Julian Lagoy, MD
Psychiatry · San Jose, CANPI 1053706861
Payments from drug & device makers
Across 314 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$825
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$652
- Lundbeck LLC$646
- Takeda Pharmaceuticals U.S.A., Inc.$579
- Axsome Therapeutics, Inc.$515
- plus $2K from 13 others
What the payments were for
- Food & beverage$7,249100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $2,163 |
| Johnson & Johnson | 28 | $825 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $652 |
| Lundbeck LLC | 26 | $646 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $579 |
| Axsome Therapeutics, Inc. | 17 | $515 |
| Otsuka America Pharmaceutical, Inc. | 20 | $436 |
| Alkermes, Inc. | 16 | $365 |
| Corium, LLC | 12 | $260 |
| Vanda Pharmaceuticals Inc. | 10 | $256 |
| Tris Pharma Inc | 7 | $170 |
| Supernus Pharmaceuticals, Inc. | 6 | $148 |
| E.r. Squibb & Sons, L.L.C. | 2 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Alfasigma USA, Inc. | 1 | $31 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$7,249 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 12 | $2,490 |
| Aripiprazole | 20 | $1,307 |
| Divalproex Sodium | 14 | $1,031 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $468 |
| Gabapentin | 25 | $433 |
| Clonazepam | 20 | $411 |
| Bupropion XlBupropion Hcl | 14 | $341 |
| Methylphenidate Hcl | 17 | $295 |
| Duloxetine Hcl | 14 | $258 |
| Sertraline Hcl | 30 | $249 |
| Trazodone Hcl | 15 | $173 |
| Fluoxetine Hcl | 13 | $169 |
| Lorazepam | 27 | $92 |
| Zolpidem Tartrate | 16 | $44 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in San Jose
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.